All Releases
 |
Dynavax and AstraZeneca Agree to Conduct Toxicology Studies for TLR-9 Agonist for Asthma
Dec 21, 2011
|
9.4 KB |
|
| |
BERKELEY, CA -- (MARKET WIRE) -- 12/21/11 --
Dynavax Technologies Corporation (NASDAQ: DVAX) and AstraZeneca announced today their decision to advance AZD1419, a proprietary second-generation TLR-9 agonist for asthma, into IND-enabling preclinical toxicology studies. These toxicology studies are scheduled to be the first module of work perform...
|
|
Dynavax Initiates Proof of Mechanism Trial in Lupus Patients
Dec 20, 2011
|
10.4 KB |
|
| |
BERKELEY, CA -- (MARKETWIRE) -- 12/20/11 --
Dynavax Technologies Corporation (NASDAQ: DVAX) announced today the initiation of a proof-of-mechanism clinical trial of the TLR7 and TLR9 inhibitor, DV1179, in systemic lupus erythematosus (SLE) patients. Initiation of this trial entitles Dynavax to receive a $6 million milestone payment from GlaxoSm...
|
|
Dynavax Announces Exercise in Full of Overallotment Option and Completion of Public Offering of Common Stock
Nov 8, 2011
|
9.8 KB |
|
| |
BERKELEY, CA -- (MARKET WIRE) -- 11/08/11 --
Dynavax Technologies Corporation (NASDAQ: DVAX) today announced the completion of a public offering of 27,600,000 shares of its common stock, including 3,600,000 shares sold pursuant to the full exercise of an overallotment option previously granted to the underwriters. All of the shares were offere...
|
|
Dynavax Prices Public Offering of Common Stock
Nov 3, 2011
|
9.9 KB |
|
| |
BERKELEY, CA -- (MARKET WIRE) -- 11/03/11 --
Dynavax Technologies Corporation (NASDAQ: DVAX) today announced the pricing of a previously announced underwritten public offering of 24,000,000 shares of its common stock, offered at a price to the public of $2.50 per share. The gross proceeds to Dynavax from this offering are expected to be $60 mi...
|
|
Dynavax Announces Proposed Public Offering of Common Stock
Nov 2, 2011
|
9.6 KB |
|
| |
BERKELEY, CA -- (MARKET WIRE) -- 11/02/11 --
Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that it intends to offer and sell shares of its common stock, subject to market and other conditions, in an underwritten public offering. Dynavax also expects to grant the underwriters a 30-day option to purchase additional shares of co...
|
|
Dynavax Confirms HEPLISAV(TM) Submission Strategies With U.S. FDA and EMA
Oct 27, 2011
|
9.5 KB |
|
| |
BERKELEY, CA -- (MARKET WIRE) -- 10/27/11 --
Dynavax Technologies Corporation (NASDAQ: DVAX) today said that the U.S. Food and Drug Administration (FDA) had concurred with the company's plan to submit a Biologics License Application (BLA) for HEPLISAV for persons over 40 years of age, followed by a supplemental BLA for licensure of a specific ...
|
|
Dynavax Reports Third Quarter 2011 Financial Results
Oct 27, 2011
|
15.2 KB |
|
| |
BERKELEY, CA -- (MARKET WIRE) -- 10/27/11 --
Dynavax Technologies Corporation (NASDAQ: DVAX) today reported financial results for the third quarter ended September 30, 2011, including $53.2 million in cash, cash equivalents and marketable securities at September 30, 2011. This amount does not include a total of $8.6 million, consisting of $6 mi...
|
|
Dynavax Phase 3 Data in Chronic Kidney Disease Demonstrates Superiority of HEPLISAV(TM) vs Engerix-B(R)
Oct 27, 2011
|
59.0 KB |
|
| |
BERKELEY, CA -- (MARKET WIRE) -- 10/27/11 --
Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that the company has unblinded its Phase 3 primary endpoint immunogenicity data in subjects with chronic kidney disease and that the data achieved statistical significance demonstrating both the superiority and non-inferiority of HEPLISA...
|
|
Data From Two Phase 3 Studies Demonstrate HEPLISAV's Superiority in Immunizing Persons With Diabetes From Hepatitis B
Oct 25, 2011
|
12.5 KB |
|
| |
BERKELEY, CA -- (MARKET WIRE) -- 10/25/11 --
Dynavax Technologies Corporation (NASDAQ: DVAX) today highlighted data from two phase 3 studies of its investigational vaccine HEPLISAV™, one of which was the first clinical trial to prospectively evaluate the effectiveness of vaccinations with recombinant hepatitis B vaccines in patients diag...
|
|
Dynavax and GlaxoSmithKline Expand Their Worldwide Strategic Alliance
Oct 21, 2011
|
9.9 KB |
|
| |
BERKELEY, CA -- (MARKET WIRE) -- 10/21/11 --
Dynavax Technologies Corporation (NASDAQ: DVAX) announced today the expansion of its worldwide strategic alliance with GlaxoSmithKline (GSK) focused on toll-like receptor (TLR) inhibitors. The addition of a new target, TLR8, entitles Dynavax to receive a $3 million milestone payment from GSK. Subjec...
|
|
Dynavax to Present at Newsmakers in the Biotech Industry Conference
Oct 14, 2011
|
7.3 KB |
|
| |
BERKELEY, CA -- (MARKET WIRE) -- 10/14/11 --
Dynavax Technologies Corporation (NASDAQ: DVAX) announced today that it plans to present at the NewsMakers in the Biotech Industry Conference in New York on Friday, October 21, 2011 at 10:00 a.m. EDT (7:00 a.m. PDT).
Dino Dina, M.D., Chief Executive Officer of Dynavax, will provide a ...
|
|
Dynavax to Host Analyst & Investor Day Webcast October 27, 2011
Oct 12, 2011
|
7.4 KB |
|
| |
BERKELEY, CA -- (MARKET WIRE) -- 10/12/11 --
Dynavax Technologies Corporation (NASDAQ: DVAX) announced today that it will webcast its 2011 Analyst & Investor Day on Thursday, October 27, 2011, from 8:00 - 11:00 a.m. Eastern Time.
Presentations and discussions by outside experts and the management team will focus on how Dynavax p...
|
|
Dynavax Reports Positive Immunogenicity Data From an Analysis of Hypo-Responsive Populations in HEPLISAV(TM) Phase 3 Trial
Oct 10, 2011
|
39.6 KB |
|
| |
BERKELEY, CA -- (MARKET WIRE) -- 10/10/11 --
Dynavax Technologies Corporation (NASDAQ: DVAX) today announced immunogenicity data for subpopulations known to be hypo-responsive (males, obese, and smokers) to currently licensed hepatitis B vaccines from its Phase 3 trial (HBV-16). The Phase 3 study was a multi-center, observer-blinded study to d...
|
|
Dynavax Reports Diabetic Subset Data From Modified Intent to Treat Analysis of the HEPLISAV(TM) Phase 3 Trial in Healthy Adults Over Age 40
Oct 6, 2011
|
10.0 KB |
|
| |
BERKELEY, CA -- (MARKET WIRE) -- 10/06/11 --
Dynavax Technologies Corporation (NASDAQ: DVAX) announced today the results of a prospective analysis of the diabetic subset population from its Phase 3 trial (HBV-16), showing the superiority of HEPLISAV vs. Engerix-B®, at all measured time points. The modified intent to treat (MITT) analysis ...
|
|
Dynavax and AstraZeneca to Advance TLR-9 Agonist Into Clinic for Asthma
Oct 5, 2011
|
10.1 KB |
|
| |
BERKELEY, CA -- (MARKET WIRE) -- 10/05/11 --
Dynavax Technologies Corporation (NASDAQ: DVAX) and AstraZeneca have amended their existing Collaboration Agreement to accelerate the initiation of clinical development of AZD 1419, a proprietary second-generation TLR-9 agonist for asthma. Dynavax will manage the early clinical development on behalf ...
|
|
Dynavax Reports Modified Intent to Treat Analysis From the HEPLISAV(TM) Phase 3 Trial in Healthy Adults Over Age 40
Oct 3, 2011
|
11.5 KB |
|
| |
BERKELEY, CA -- (MARKET WIRE) -- 10/03/11 --
Dynavax Technologies Corporation (NASDAQ: DVAX) presented yesterday at the 5th Global Vaccine Congress in Seattle, WA an analysis of the modified intent to treat population from its Phase 3 trial (HBV-16), showing the superiority of HEPLISAV vs. Engerix-B®. The previously reported per protocol ...
|
|
Dynavax Reports Complete Results From the HEPLISAV(TM) Phase 3 Trial in Healthy Adults Over Age 40
Sep 18, 2011
|
11.6 KB |
|
| |
BERKELEY, CA -- (MARKET WIRE) -- 09/18/11 --
Dynavax Technologies Corporation (NASDAQ: DVAX) today at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Chicago, IL presented complete results for the entire study population of its Phase 3 trial (HBV-16). The Phase 3 study, HBV-16, was a multi-center, observer-...
|
|
Dynavax to Report Additional Immunogenicity Data for HEPLISAV(TM) Phase 3 Trial
Sep 16, 2011
|
7.7 KB |
|
| |
BERKELEY, CA -- (MARKET WIRE) -- 09/16/11 --
Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that on Sunday, September 18, at 11:30 am CDT at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), the company will present additional immunogenicity data from its Phase 3 trial (HBV-16) evaluating the im...
|
|
Dynavax to Present at the UBS Global Life Sciences Conference
Sep 16, 2011
|
7.2 KB |
|
| |
BERKELEY, CA -- (MARKET WIRE) -- 09/16/11 --
Dynavax Technologies Corporation (NASDAQ: DVAX) announced today that it plans to present at the UBS Global Life Sciences Conference in New York on Tuesday, September 20, 2011 at 3:30 pm EDT (12:30 pm PDT).
Michael S. Ostrach, Vice President and Chief Business Officer of Dynavax, will p...
|
|
Dynavax Receives $600,000 SBIR Grant for TLR Research
Sep 7, 2011
|
8.6 KB |
|
| |
BERKELEY, CA -- (MARKET WIRE) -- 09/07/11 --
Dynavax Technologies Corporation (NASDAQ: DVAX) today announced the receipt of a two-year Small Business Innovation Research grant (SBIR) for $600,000. The Award is provided by the National Institute of Allergy and Infectious Diseases and will be used to fund research to characterize the role of the...
|
|
|
